Illumina Files IPO Prospectus to Democratize Genomic Testing with Consumer-Focused Products

Illumina is the undisputed leader in DNA sequencing, an emerging field in the United States, monopolizing more than 75% of the market share for sequencing equipment. SimilarlyThe genetic testing instruments owned by 23andMe, a direct-to-consumer genetic research company with Google ties, were manufactured by this biotechnology giant valued at $25 billion. Moreover, nearly all of China’s well-known mid- and downstream gene sequencing enterprises have also adoptedIllumina products.

This time, Illumina is going direct-to-consumer with a consumer-grade product, aiming to popularize genetic sequencing and facilitate early disease screening and diagnosis of rare diseases. In the current era where comprehensive health management is gaining momentum, this is no small feat. For less than $3,000, users can determine their resistance to certain medications or identify whether they carry gene mutations associated with an increased risk of breast and ovarian cancer.

The company is headquartered in San Diego, sharing some similarities with Silicon Valley’s tech parks: a comfortable work environment, complete with cafés and canteens. Senior executives work in the same open space as everyone else, with no private offices.

As a well-established company, Illumina was founded in 1998 and is dedicated to advancing new DNA sequencing technologies, applying them to the growing clinical and consumer markets, thereby becoming an indispensable part of the DNA ecosystem.

Former CEO Jay Flatley is regarded as the foremost champion of the company’s culture of innovation and has made substantial contributions to its growth and development. The company now boasts 5,000 employees and annual revenues exceeding $2 billion. Yet back in 2003, just five years after its founding, it was merely eking out a profit while competing against larger corporations.

Surrounded by formidable rivals, Illumina has competed with many large corporations, but the most intense competition was the strategic M&A battle with Roche. On Marc Stapley’s first day as Illumina’s Chief Financial Officer, Roche launched a hostile takeover. Illumina’s bankers believed that acquisition by Roche was only a matter of time, but Jay Flatley and the shareholders were outraged. Jason Young, the third-largest shareholder, even declared that Illumina would not be sold to Roche at any price. Ultimately, Roche abandoned its acquisition attempt. Today, Illumina’s market capitalization exceeds four times the amount of Roche’s original offer. Through this hostile takeover attempt by Roche, Flatley recognized an opportunity to enter the healthcare market.

“Integration of talent, processes, and product development through innovation,” recalled founder and former COO John Stuelpnagel. “This innovative capability was, to some extent, ignited by competitors, much like the ‘catfish effect.’”

The situation began to change when Flatley acquired Solexa, a UK-based biotech startup with “synthetic sequencing” technology. In 2007, Illumina researchers improved the core technology, and the company also established a global distribution network. The executive team made several improvements to the marketing model, enabling rapid product launches across multiple geographic locations.

A milestone in the company’s development history was the proposal of Flatley’s new strategy. In 2009, Flatley established a CLIA-certified laboratory to leverage advantages in new hardware testing and demonstrate the capabilities of next-generation sequencing.

Flatley further promoted consumer genomics through the Understand Your Genome (UYG) Project, launching sequencing and analysis services that offer greater depth than those provided by 23andMe and earlier generations of products. For less than $3,000, users can determine their drug resistance profiles or identify genetic mutations associated with an increased risk of breast and ovarian cancer. Erica Ramos, a genetic counselor involved in the UYG project, stated that they identified genetic mutations in 2% of participants.

The company has also made numerous attempts to promote public understanding of gene sequencing through practical applications. In the past, DNA sequencing was conducted within laboratories filled with rows of computers of varying sizes. The HiSeq X Ten is approximately the size of an office copier, while enabling faster and more cost-effective gene sequencing.

Moreover, the company offers specialized low-end instruments, comparable in size to a desktop computer, primarily sold to molecular biologists, pathologists, and oncology patients, at a price of approximately $50,000.

Illumina’s instruments have captured more than 70% of the sequencing market, serving customers such as academics, pharmaceutical companies, and biotechnology firms. Among these, the HiSeq X Ten has 35 customers, including the Garvan Institute of Medical Research in Sydney and the Broad Institute at the University of Cambridge. These customers are sometimes referred to as the “X Ten Club.”

Under Jay Flatley’s leadership, the company became the undisputed leader in the industry.

During Flatley’s tenure, a rigorous product execution mechanism was established, earning the company a strong reputation. In 2014, it became the first to announce that the cost of gene sequencing would be reduced to $1,000, thereby solidifying its position in the industry. Today, Illumina holds a pivotal role in genomics.

Like any other large company, Illumina also faces challenges to the stable position of its core business.

On one hand, there is pressure from continuously evolving technologies. The UK’s initiative includes a technology called Oxford Nanopore, which can manufacture small, portable sequencing instruments. It claims to be usable on-site and provide real-time reports, and has even been used on the International Space Station. Oxford Nanopore technology reads long strands of DNA by measuring changes in electrical current caused by nucleotides passing through microscopic pores. Moreover, it has shown potential in the rapid diagnosis of the Zika virus.

Another challenge stems from competition with partners. Currently, Illumina is in a competitive relationship with nearly every genomics company, which makes its entry into the clinical market somewhat difficult.

Previously, Illumina did not compete with its customers, but this dynamic changed when the company entered the clinical sector. In September 2012, Illumina acquired Blue Gnome, a UK-based genetic variant sequencing services company. Then, in January 2013, Illumina further acquired Verinata Health for $350 million. The announcement sent shockwaves through the industry, as Verinata was a direct competitor to Illumina in the field of non-invasive prenatal testing (NIPT). Verinata possessed technology capable of detecting chromosomal abnormalities by analyzing fetal DNA in maternal blood—a technology now valued at $1 billion.

In July of the following year, Illumina made another move by acquiring Myraqa, a consulting firm specializing in companion diagnostics and other IVDs, paving the way for the application of genomics technologies in regulated markets while promoting clinical standards.

Christian Henry, Illumina’s Chief Business Officer, stated, “For Illumina, the fundamental question is how many customers it competes with.” Henry emphasized that the company has begun to pursue a “boutique strategy,” avoiding direct sales to physicians. Instead, Illumina has defined its target customers as laboratories or other NIPT companies seeking to utilize its equipment. “Illumina aims to democratize genetic sequencing and make NIPT sequencing accessible in every laboratory,” added Groberg.

In 2009, Jay Flatley, then CEO of Illumina, learned that he had malignant hyperthermia, a condition that put him at risk of death from general anesthesia at any time. Flatley sent samples of his blood and saliva to the company’s newly established laboratory for genetic testing.

It took the laboratory several weeks and tens of thousands of dollars to deduce the genomic sequence. Due to the prescription requirements from Flatley’s physician, the scientists made certain medical discoveries. “We were under significant pressure at the time, but we also achieved many world-first findings,” said Brad Sickler, the company’s bioinformatician. “Jay is the tenth person in the world to undergo deep sequencing.”

Jaynome’s experimental results hint at a potential possibility: bringing gene sequencing into clinical care. “Many diseases may be preventable, but for most people, they have little opportunity to access such measures,” said Flatley.

The Jaynome project has inspired Flatley to pave the way for the widespread adoption of genetic information. The company has played a pivotal role in this endeavor by introducing lower-cost, user-friendly testing instruments.

The cost of genetic testing has dropped from $100 million in 2001 to $1,000 today, with Illumina playing a pivotal role in this transformation. As Nature magazine once noted, “What they have achieved has surpassed Moore’s Law, delivering highly accurate predictions for random variants.”

Previously, the process of gene sequencing typically took several weeks, but now it requires only three days; Illumina’s HiSeq X Ten sequencer can sequence the genomes of 16 individuals. This machine is capable of completing genomic sequencing for 18,000 people annually. Meanwhile, this technology is rapidly transitioning from laboratory settings to hospitals, clinics, and even homes.

Nowadays, genomics has been endowed with significant value and plays a crucial role in the study of genetic disorders and rare diseases, including some rare conditions that cannot be diagnosed using traditional methods.

In Australia, a young boy named Massimo lost the ability to swallow and crawl. His father suspected that this might be a genetic disorder and sought help from Illumina.

Massimo became the 45th person in the world to undergo whole-genome sequencing using Illumina technology, followed by his parents. As both of Massimo’s parents are healthy, it suggests that the underlying issue may stem from certain DNA variants. Ryan Taft, an executive, explained that this requires assembling and reassembling the family’s genomes 30 to 40 times to ensure there are no errors. These sequences comprise approximately 12 billion base pairs.

Leveraging existing open-source frameworks, Taft developed an algorithm. Ultimately, they identified a mutation in Massimo’s genome that potentially explained these symptoms. To validate this hypothesis, Taft began searching for sequences similar to Massimo’s. With the assistance of the MRI Biobank, nine similar cases were eventually identified across Europe and the United States. Finally, they named this new disease HBSL.

With the widespread adoption of genomics, rare disease experts anticipate that the repository of genetic disease information will expand. Treatments will be tailored to different diseases based on mutation specificity, drugs will have a greater impact, and clinical trials will achieve higher success rates.

Recently, the company partnered with Alphabet to launch the “Moonshot” initiative.CurrentFrancis deSouza, CEO and MIT Computer Scientist, to InvestSplit intoGrail and Helix,Hope to further promoteDNA Enters Everyday Life.This will introduce a new model to DNA informatics—the app store model—and make early cancer screening accessible in every doctor’s office.

The company invested $100 million in Helix1, a spin-off software venture from the startup BaseSpace. Helix’s strategy involves partnering with well-known brands to create targeted, personalized genomics applications available for download via the Apple App Store. Through an app developed by a nutrition company, customers can assess their rate of caffeine metabolism. Helix sequences and centrally stores customers’ genomic data, after which the nutrition company provides the reports back to the customers.

At the same time, genomic data is not returned to customers in a single batch; instead, it addresses specific questions based on particular needs, which requires Helix and its partners to develop new apps.

Meanwhile, Helix needs to establish a vast network of partners so that customers can find the genomic insights they are looking for. Another distinction from consumer genomics applications like 23andMe is that Helix offers exome sequencing. In other words, it provides more valuable information compared to traditional offerings. This will mark the first widespread application of deep sequencing in the consumer market.

“We are interested in Helix’s theory and how the company uses its platform.” When asked about its views on this competitor, 23andMe stated, “This also reinforces our confidence in the consumer market we have pioneered over the past decade.”

Helix will launch its first batch of customers later this year, including Mayo Clinic, LabCorp, and Duke University.

2.Grail

In 2015, the White House allocated $215 million as funding for the “Precision Medicine Initiative,” with a primary focus on cancer. Precision medicine has once again become a hot topic:

Each tumor cell harbors distinct mutations, laying the foundation for designing novel therapeutic approaches that enable physicians to tailor treatments to individual patients. This paradigm will fundamentally transform the field of oncology.

Illumina also seems to agree with this view: it invested $100 million to establish the world’s first FDA-approved cancer screening laboratory.

Grail is a new company established by Illumina that enables early cancer diagnosis by analyzing high-resolution genetic fragments from dying tumor cells, allowing patients to receive treatment before the disease progresses. Currently, this technology is being used to monitor disease status in patients with confirmed cancer diagnoses.

Such testing requires a high degree of precision; otherwise, it would lead to the risk of clinical misdiagnosis. However, Flatley is confident that the new company can overcome countless technical challenges. He believes that Illumina is the only company with deep sequencing capabilities.

In 2017, Grail is expected to launch its “largest clinical trial.” Meanwhile, Grail will also screen for approved products to enter the market, with plans to reduce the price to below $1,000 by 2019. The initiative has secured investments from Bill Gates and Jeff Bezos, and its potential market value has been hyped to between $20 billion and $40 billion.

If Grail and Helix succeed, DNA testing will become part of more people’s lives. Personal genome sequencing will also become commonplace, beginning before birth and continuing throughout one’s lifetime. It is no wonder that Illumina refers to the final phase of its master plan as “Genomics Everywhere.”

“I believe that many people, including myself, have envisioned a future in which genomics is integrated into every individual within the healthcare system,” explained Ashley, a geneticist at Stanford University.

Many researchers believe that as genomics becomes more widespread, preventive care will also become more routine: when patients understand their unique disease risks, they can take proactive measures to reduce them; or cancer cells can be effectively detected before they spread.

Having achieved the ability to read DNA, the next step is editing it. Gene editors such as CRISPR-Cas9 have enabled low-cost and rapid gene manipulation, holding significant promise for environmental improvement and disease treatment.

Stuelpnagel believes that over the next decade, Illumina will have a greater impact on health and agriculture than any other company. DNA is the genetic code of life, and Illumina enables people to deepen their understanding of it. Mastering gene-editing technology equates to achieving precise genetic manipulation, which will undoubtedly further strengthen Illumina’s competitive advantage.